Anavex Life Sciences Corp. AVXL
As ofNov 16, 2026, 1:37 PM EST
- YTD
- -76.40%
- 1 year
- -76.92%
- Market cap
- 77.88M
- EPS (ttm)
- -0.14
- Shares out
- 84.80M
- Forward P/E
- -17.25
- YTD return
- -76.40%
- 1-year return
- -76.92%
- 50-day average
- 7.73
- 200-day average
- 5.65
- Enterprise value
- 593.03M
- Volume
- 1.18M
- Avg volume
- 1.05M
- Open
- 0.94
- Previous close
- 0.9335
- Day's range
- 0.8351 – 0.95
- 52-week range
- 0.8351 – 5.36
- Beta
- 0.60
- Analysts
- Strong Buy
- Price target
- 35.47 (+4121.9%)
5D -0.3164 (-26.81%)
Key statistics
- Price / book
- 7.10
- Free cash flow
- -19.06M
- Total cash
- 138.76M
- Return on equity
- -30.03%
- Short % of float
- 23.96%
Fundamental scorecard
7 of 25 checks passed on AVXL’s reported financials
7of 25 checks passed
- Value 1 of 5
- Growth 1 of 5
- Profitability 0 of 5
- Financial health 5 of 5
- Dividend 0 of 5
Statements to Jun 30, 2026.
Financials — quick view
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 23, 2024 | D. Boral Capital | main | Buy | Buy |
| Nov 27, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Nov 26, 2024 | D. Boral Capital | main | Buy | Buy |
| Nov 25, 2024 | D. Boral Capital | main | Buy | Buy |
| Nov 4, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Oct 31, 2024 | EF Hutton | main | Buy | Buy |
About Anavex Life Sciences Corp.
Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome. The company's drug candidate also comprises ANAVEX 3-71, which is in clinical trial for the treatment of schizophrenia, frontotemporal dementia, and Alzheimer's disease. Its preclinical drug candidates include ANAVEX 1-41 for the treatment of depression, stroke, and neurogenerative disease; ANAVEX 1066 for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- anavex.com
News
SHAREHOLDER ALERT: Bronstein Gewirtz & Grossman, LLC Announces Class Action Against Anavex Life Sciences Corp. (NASDAQ: AVXL) — Investors Who Suffered Losses Are Encouraged to Contact the Firm
Kaplan Fox Reminds Investors of the November 30, 2026 Deadline in the Securities Class Action Against Anavex Life Sciences Corp. (AVXL)
AVXL DEADLINE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Anavex Life Sciences Corp. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – AVXL
AVXL DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Anavex (AVXL) Investors of Securities Class Action Lawsuit Deadline on November 30, 2026
AVXL DEADLINE: ROSEN, TOP-RANKED INVESTOR RIGHTS COUNSEL, Encourages Anavex Life Sciences Corp. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - AVXL
Kaplan Fox Announces the Lead Plaintiff Deadline of November 30, 2026 in the Securities Class Action Against Anavex Life Sciences Corp. (AVXL)
Did You Lose Money on Anavex Life Sciences Corp. Stock? Faruqi & Faruqi, LLP Reminds Investors of November 30, 2026 Lead Plaintiff Deadline in Securities Class Action After 34.61% Share Price Decline
Anavex Life Sciences Corp. Investors Seeking Lead Plaintiff Role Have Until November 30th to Contact Bragar Eagel & Squire, P.C.
AVXL DEADLINE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Anavex Life Sciences Corp. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – AVXL
SHAREHOLDER ALERT: Bronstein Gewirtz & Grossman, LLC Announces Class Action Against Anavex Life Sciences Corp. (NASDAQ: AVXL) — Investors Who Suffered Losses Are Encouraged to Contact the Firm
Your note
Sign in to keep a note on AVXL — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| DONHAUSER PETER D.O. | Director | Purchase | Jun 13, 2024 | 5,000 |
| MISSLING CHRISTOPHER U | Chief Executive Officer | Sale | Mar 27, 2024 | 1,250,210 |
| THOMAS STEFFEN PHD | Director | Purchase | May 14, 2024 | 5,000 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 7.95% | 6,740,696 | 73.27M | Sep 29, 2024 |
| Vanguard Group Inc | 5.59% | 4,740,171 | 51.53M | Sep 29, 2024 |
| State Street Corporation | 3.62% | 3,065,947 | 33.33M | Sep 29, 2024 |
| Geode Capital Management, LLC | 2.22% | 1,883,199 | 20.47M | Sep 29, 2024 |
| NWAM LLC | 1.07% | 910,476 | 9.90M | Sep 29, 2024 |
| Two Sigma Investments, LP | 0.98% | 830,624 | 9.03M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 2.99% | 2,534,500 | 27.55M | Sep 29, 2024 |
| iShares Russell 2000 ETF | 2.30% | 1,946,169 | 21.15M | Oct 30, 2024 |
| SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF | 1.89% | 1,604,415 | 17.44M | Sep 29, 2024 |
| Vanguard Extended Market Index Fund | 1.57% | 1,331,918 | 14.48M | Sep 29, 2024 |
| Fidelity Small Cap Index Fund | 0.88% | 746,316 | 8.11M | Aug 30, 2024 |
| iShares Biotechnology ETF | 0.69% | 581,949 | 6.33M | Oct 30, 2024 |
